69010
document
Ranibizumab plus verteporfin photodynamic therapy in neovascular age-related macular degeneration : 12 months of retreatment and vision outcomes from a randomized study . PURPOSE To investigate the injection frequency and visual acuity ( VA ) outcomes with combination therapy ( ranibizumab plus verteporfin photodynamic therapy , PDT ) versus monotherapy ( ranibizumab ) . METHODS A total of 40 patients with exudative age-related macular degeneration were randomized 1:1 to ranibizumab 0.3 mg plus single standard verteporfin PDT or ranibizumab 0.3 mg plus sham PDT . Ranibizumab was administered 3 times monthly followed by 'as needed ' to month 12 based on predetermined vision/anatomical criteria . Retreatment rates , VA outcomes and safety were assessed . RESULTS During months 3-12 , combination therapy patients required fewer ranibizumab injections ( mean 1.3 ) compared with monotherapy patients ( 2.8 ) . Mean VA improved by 9.0 letters with combination therapy versus 7.5 letters in the monotherapy group at month 12 . Both treatment regimens were well tolerated . CONCLUSION The need for ranibizumab retreatment might be reduced by administering a single verteporfin PDT on the same day as the first ranibizumab injection , without compromising VA outcomes or safety .
69011
Intervention_Pharmacological
Ranibizumab
69012
Intervention_Pharmacological
verteporfin
69013
Intervention_Pharmacological
ranibizumab plus verteporfin photodynamic therapy , PDT )
69014
Intervention_Pharmacological
ranibizumab
69015
Intervention_Pharmacological
ranibizumab
69016
Intervention_Pharmacological
single standard verteporfin PDT
69017
Intervention_Pharmacological
ranibizumab
69018
Intervention_Pharmacological
sham PDT
69019
Intervention_Pharmacological
Ranibizumab
69020
Intervention_Pharmacological
ranibizumab
69021
Intervention_Pharmacological
ranibizumab
69022
Intervention_Pharmacological
verteporfin PDT
69023
Intervention_Pharmacological
ranibizumab
69024
Participant_Sample-size
40 patients
69025
Participant_Condition
exudative age-related macular degeneration were randomized